BALANCE OF PROINFLAMMATORY AND ANTI INFLAMMATORY MARKERS IN ROUTINE HEMODIALYZED PATIENTS (A STUDY OF END-STAGE RENAL FAILURE PATIENTS AT THE DR. SARDJITO HOSPITAL YOGYAKARTA)
DOI:
https://doi.org/10.24293/ijcpml.v24i2.1317Keywords:
End stage renal disease, hemodialysis, proinflammatory markers, anti-inflammatory markersAbstract
Patients with End-Stage Renal Disease (ESRD) tend to have immune imbalance triggered by uremia and Hemodialysis (HD) procedures. Contact between dialysis membrane and blood will cause bio-incompatibility reactions inducing complement activation and production of Reactive Oxygen Species (ROS) as well as proinflammatory cytokines and acute phase protein such as C-Reactive Protein (CRP). Those immune response imbalances will lead to an immunocompromised condition. The objective of this study was to prove the correlation between inflammatory markers (IL-1β, IL-6 and C-reactive proteins) and its anti-inflammatory marker (IL-10) in routine hemodialyzed patients. This is a cross-sectional observational study involving 90 subjects conducted at the Hemodialysis Installation of the Dr. Sardjito Hospital. The inclusion criteria of this study were patients who underwent routine HD procedures, aged between 18 and 65 years-old, having leukocytes count and albumin level within normal limit. The exclusion criteria of this study were patients with Acute Coronary Syndrome (ACS) and malignancies. Levels of IL-1β, IL-6 and IL-10 were measured using Enzyme-Linked Immunosorbent Assay (ELISA), while CRP was measured using highly-sensitive CRP immunoturbidimetry. Statistical analysis was performed by Spearman test. This study results showed correlations between IL-1βand IL-10 (p=0.001, r=0.302), IL-6 and IL-10 (p=0.001, r=0.418) and correlation between CRP and IL-10 (p=0.005, r=0.295). There were also correlations between IL-1β and IL-6 (p=0.029, r=0.232), IL-6 and CRP (p=0.001, r=0.534), but no correlation was found between IL- 1β and CRP (p=0.431, r=0.073). All factors that trigger the secretion of proinflammatory cytokines will trigger the release of anti-inflammatory cytokines, the consequences of anti-inflammatory cytokine secretion will happen minutes after the release of inflammatory cytokines. This study showed that there were correlations between proinflammatory and anti-inflammatory cytokines. Further studies of polymorphism-related cytokines secretion are warranted.
Downloads
References
Coresh J, Selvin E, Stevens LA. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298(17): 2038–47.
Nagane NS, Ganu JV, Jagtap PE. Study of oxidative stress in pre- and post-hemodialysis in chronic renal failure patients. Biomed Research 2013; 24(4): 498-502.
Brown MD, Feairheller DL, Thakkar S, Veerabhadrappa, Park JY. Racial differences in tumor necrosis factors a-indiced endothelial microparticles and IL-6 production. Vascular Health and Risk Management 2011; 7: 541-550.
Tripathi G, Rangaswamy D, Borkar M, Prasad N, Sharma RK, Sankhwar SN, Agrawal S. Interleukin-1 gene cluster variants in hemodialysis patients with end stage renal disease: An association and meta-analysis. Indian Journal of Nephrology 2015; 25(1): 34-42.
Nand N, Aggarwal HK, Yadav RK, Gupta A, Sharma M. Role of high-sensitivity C-reactive Protein as a Marker of Inflammation in pre-dialysis patients of chronic renal failure. JIACM 2009; 10(1 & 2): 18-22.
Kamel L, Morsy A, El Shamaa A. T-cell cytokine production and endothelial dysfunction in type 2 diabetic patients with nephropathy. Eastern Mediterranean Health Jour 2009; 15(4): 807-16.
Krishnamurthy N, Arugasany K, Anand U, Anand CV, Aruna V, Venu G, Gayathri R. Effect of hemodialysis on circulating cystatin c levels in patients with end stage renal disease. Indian Jour of Clin Biochem 2010; 25(1): 43-46.
Hendrikx TS, Van Gurp EA, Mol WM, Schoordijk W, Sewgobind VDK, Ijzermans JNM, Weimar W, Baa CC. End-stage renal failure and regulatory activities of CD4+ CD25 bright+FoxP3+ T cells, Nephrol Dial Transplant 2009; 4: 1969-78.
Jeli M, Cvetkovi T, Djordjevi V, Damnjanovi G, Vlahovi P, Koci G, et al. Hepcidin and iron metabolism disorders in patients with chronic kidney disease. Vojnosanit Pregl 2013; 70(4): 368–373.
Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128(2): 127–137.
Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev 2010; 21(5): 315-24.
Nordfors L, Lindholm B, Stenvinkel P. End-stage renal disease--not an equal opportunity disease: the role of genetic polymorphisms. J Intern Med 2005; 258(1): 1-12.
Stevinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits R, Riella M, Heimburger O, Cederhom T, Girndt M. IL-10, IL-6 and TNFa: Central factors in the altered cytokine network of uremia-The good, the bad and the ugly. Kidney International 2005; 67(4): 1216–1233.
Yhee JY, Yu CH, Kim JH, Sur JH. Effects of T lymphocytes, interleukin-1 and interleukin-6 on renal fibrosis in canine end-stage renal disease. J Vet Diagn Invest 2008; 20(5): 585-92.
Niskane A, Saramäki M, Schwandt E. Myeloperoxidase (MPO) and hs-CRP as predictive factors for myocardial infarction. CLI, 2006; 7: 38-9.
Girndt M, Kohler H, Weick ES, Schlaak JF, Meyer KH, Fleisher B. Production of interleukin-6, tumor necrosis factor a and interleukin 10 in vitro correlates with the clinics; immune defect in chronic hemodialysis patients, Kidney Int. 1995; 47: 559-65
Manchanda PK, Singh R, Mittal RD. Cytokine (IL-10 _1082 and _819) and chemokine receptor (CCR2 and CCR5) gene polymorphism in north indian patients with end-stage renal disease. DNA and Cell Biology 2009; 28(4): 177-83.
Okada R, Wakai K, Naito M, Morita E, Kawai S, Hamajima N, Takashima N. Pro-/anti-inflammatory cytokine gene polymorphisms and chronic kidney disease: a cross-sectional study. BMC Nephrology 2012; 13(2): 1-8.
Elshama MF, Sabry S, Galal A, Koura H, Kantoush N, Rasheed M, Thabe EH. Serum interleukin 10 levels in vascular access failure in Egyptian children on hemodialysis. J Clin Basic Cardiol 2009; 12(1): 18–23.
Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128(2): 127–137.
